Articles from Dyno Therapeutics, Inc.

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced the launch of three new adeno-associated virus (AAV) capsid gene delivery vectors targeting the eye, musculoskeletal system and central nervous systems (CNS), each with best-in-class potential. Key data from the capsids were presented in a Scientific Symposium at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting and in three oral abstract presentations.

Dyno Therapeutics, Inc., a genetic technologies company applying AI to enable safe and effective in vivo delivery of genetic medicines, today announced two new initiatives designed to accelerate progress across the gene therapy field: the inaugural Genetic Agency Technology Conference (GATC) and the Dyno Frontiers Program for innovative therapeutic developers. Details were shared during the company’s Scientific Symposium at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that it will present a broad set of data related to the design of novel capsids targeting the eye, brain, and neuromuscular system using frontier AI during a Scientific Symposium and three oral presentations at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that Roche (SIX: RO, ROG; OTCQX: RHHBY) has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease indication. The capsid license is pursuant to the agreement between Dyno and Roche originally announced in May 2020.

Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential of genetic medicine, today hosted a Scientific Symposium at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held in Baltimore, MD.

Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential of genetic medicine, today announced a Scientific Symposium and the presentation of three research abstracts, including one oral presentation, at the upcoming 27th Annual Congress of the American Society of Gene & Cell Therapy (ASGCT) being held May 7-11th, 2024 in Baltimore, Maryland. That same week Dyno Therapeutics will also be giving two talks on the theme of Machine Learning at SynBioBeta’s Global Synthetic Biology Conference held from May 6-9th, 2024 in San Jose, California.

Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that can expand the potential of genetic medicine, today announced the launch of its Dyno eCap 1™ capsid product, a leading eye AAV gene delivery vector with best-in-class potential, in a keynote address at the company’s Scientific Symposium at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT). The Dyno eCap 1 vector provides significantly improved delivery to the eye compared to other externally engineered capsids, including transduction throughout multiple layers of the retina.

Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that expand the potential of genetic medicine, today announced a Dyno Scientific Symposium and the presentation of three research abstracts at the upcoming 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) being held October 24-27, 2023 in Brussels, Belgium.

Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that can expand the potential of genetic medicine, today announced the launch of its Dyno bCap 1™ capsid product, a breakthrough CNS-targeted AAV gene delivery vector with best-in-class potential, in a keynote address at the company’s Scientific Symposium at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting. The Dyno bCap 1 vector provides dramatically improved CNS delivery and liver detargeting compared to leading natural capsids and stronger all-around characteristics relative to other engineered CNS-IV capsids.

Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that can expand the potential of genetic medicine, today announced a Dyno Scientific Symposium and the presentation of four research abstracts at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 16-20, 2023 in Los Angeles, Calif.

Dyno Therapeutics, a biotechnology company applying artificial intelligence (AI) to gene therapy, will describe ongoing enhancements to its machine learning platform in three oral presentations at the 24th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place virtually from May 11-14, 2021.

Dyno Therapeutics, Inc., a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. Funds from this financing will directly fund expansion of the company’s CapsidMap™ platform, which uses AI technology for the design of novel Adeno-Associated Virus (AAV) gene therapy vectors, broadening the functionality and enhancing the therapeutic impact of gene therapies developed by Dyno’s biopharmaceutical partners.